10. April 2017

Updated health economic analysis Palbociclib

Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.

Matter-Walstra K, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2017 Mar 21. doi: 10.1007/s10549-017-4209-5. [Epub ahead of print] No abstract available.

 

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ.

Breast Cancer Res Treat. 2016 Jul;158(1):51-7. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8.

Tags: work, cancer
Kommentare: 0

Sa

27

Jan

2024

Publication

Sa

27

Jan

2024

Croatia-Montenegro sailing

Sa

27

Jan

2024

Newest Art

Mi

10

Mai

2023

Croatia Mai-June 2023

Di

11

Okt

2022

Croatia 2022

Fr

18

Jun

2021

Sailing 2021

mehr lesen